Úskalí léčby chronické myeloidní leukemie dasatinibem - plicní arteriální hypertenze jako vzácná komplikace
| Title in English | Pitfalls of treating chronic myeloid leukaemia with dasatinib - pulmonary arterial hypertension as a rare complication |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Transfuze a hematologie dnes |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/2021-2-21/uskali-lecby-chronicke-myeloidni-leukemie-dasatinibem-plicni-arterialni-hypertenze-jako-vzacna-komplikace-127610 |
| Doi | http://dx.doi.org/10.48095/cctahd2021166 |
| Keywords | chronic myeloid leukaemia; dasatinib; pleural effusions; pulmonary arterial hypertension |
| Description | Dasatinib is a potent tyrosine kinase inhibitor of not only Bcr-Abl1, but also of the Src kinase family, c-kit and PDGFR-b. This “offtarget” effect is the probable cause of pleural effusions, which complicate dasatinib therapy in about one third of patients. The following case report describes a chronic myeloid leukaemia patient with not only recurrent pleural effusions but also pulmonary arterial hypertension as a serious adverse event leading to dasatinib discontinuation. |
| Related projects: |